Ackman, in email, says supports Valeant CEO Pearson
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
Go back to Ackman, in email, says supports Valeant CEO Pearson
November 6, 2015 6:29 AM EST
Guggenheim analyst Louise Chen lowered her price target on Valeant Pharmaceuticals (NYSE: VRX) to $195.00 (from $300.00) but maintained a Buy rating saying the investment thesis remains intact.
Chen commented, "We are lowering our PT for VRX to $195 from $300. The decrease in our PT is... More
November 5, 2015 3:42 PM EST
With all hope lost, speculators wonder if a fire sale may be the last resort to stop the bleeding in Valeant Pharma (NYSE: VRX) shares.
Trades are keenly focusing on the last line in Bill Ackman's letter supporting Valeant Pharma... More
November 5, 2015 3:13 PM EST
Mizuho Securities analyst Irina Koffler said worse case analysis and Valeant Pharmaceuticals (NYSE: VRX) is a Buy. The firm reiterated a Buy rating and $155 price target.
The stock is no longer trading on fundamentals in our view. We look at a liquidation valuation in the extreme case that management is ousted and the business is put up for sale under distressed conditions. We conclude shares are undervalued and reiterate our BUY rating
Key points:
We try to remain rational and reiterate our BUY rating: We understand the...
More
